Want to Stay Current on Latest in Cancer Prevention and Treatment? Free Service from NCCN Can Help
Weekly updates from the National Comprehensive Cancer Network share every time a…
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colore
This positive CHMP opinion is based on results from the Phase 3…
Longeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a…
Novi GLP-1 Weight Loss Claims Evaluated: Trusted Semaglutide & Tirzepatide Prescription Medication Treatment Options with Dedicated Doctors
Sheridan, WY, May 07, 2026 (GLOBE NEWSWIRE) -- Compounded medications are not…
PFCD Advocates for Insurance Coverage of Robotic Joint Replacement Surgery to Bridge India’s Treatment Gap
NEW DELHI, April 30, 2026 /PRNewswire/ -- The Partnership to Fight Chronic…
Nxera Pharmas QUVIVIQ (daridorexant) 25mg and 50mg Receives Approval in Taiwan for the Treatment of Insomnia
Nxera’s partner Holling Bio-Pharma Corp. will commercialize QUVIVIQ® in Taiwan, a market with…
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
April 10, 2026 17:02 ET | Source: Replimune, Inc. WOBURN, Mass., April…
Overcoming Onychomycosis Claims Evaluated: Blue Heron Health News Nail Fungus Treatment Program is On Sale
Boise, ID, April 03, 2026 (GLOBE NEWSWIRE) -- This release is based…
New SPRAVATO (esketamine nasal spray) data support robust effectiveness and show durable effect for treatment resistant depression in a real-world setting
Johnson & Johnson presents findings from the largest European real-world dataset for…
CityUHK researchers unveil the mystery of “Asian Flush” mechanism, pioneering new directions in precision treatment for heart attacks
HONG KONG, March 12, 2026 /PRNewswire/ -- Approximately 40% of the East…
